会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • 패혈증 단백질 치료제의 효능 분석 및 스크리닝 방법
    • 筛选蛋白质治疗剂的方法
    • KR1020120107741A
    • 2012-10-04
    • KR1020110025446
    • 2011-03-22
    • 한국생명공학연구원한국과학기술원
    • 이승구김학성김유정이상철한지은이상준김수진손정훈하재석
    • C12Q1/02C12N15/63G01N33/15G01N33/53
    • C07K14/195C07K14/46C07K14/461C07K14/705C07K2319/35C07K2319/70C12N15/70C12Q1/6897G01N33/5023G06F19/16
    • PURPOSE: An assay system for screening a therapeutic agent is provided to maintain structural stability and to analyze the efficacy of a protein therapeutic agent. CONSTITUTION: A method for analyzing the efficacy of a protein therapeutic agent for treating sepsis comprises: a step of transducing a vector with an expression cassette containing a NF-kappaB which binds a motif-conjugated promoter and a gene encoding a reporter protein, and a vector with an expression cassette containing NF-kappaB which binds a motif-free promoter and a gene encoding the reporter protein into a cell line on which an LPS signal transduction receptor is expressed; a step of mixing purified MD-2(myeloid differentiation protein-2), LPS and protein therapeutic agent for treating sepsis; a step of contacting the mixture with the cell line; and a step of determining whether a contacted experimental group has a higher efficacy than a control group when expression level of the reporter protein is less than the control group. [Reference numerals] (AA) Luciola cruciata luciferase; (BB) Renilla luciferase; (CC) LAR II reagent; (DD) Stop&Glow reagent; (EE) Firefly/Renilla = TLR4/MD-2 activation index; (FF) TMB substrate; (GG) Cytokine TNF-alpha, IL-6, etc.
    • 目的:提供用于筛选治疗剂的测定系统以维持结构稳定性并分析蛋白质治疗剂的功效。 构成:用于分析蛋白质治疗剂用于治疗败血症的功效的方法包括:用含有结合基序缀合的启动子的NF-κB和编码报道蛋白的基因的表达盒转导载体的步骤,以及 载体,其含有含有免疫启动子和编码报告蛋白的基因的NF-κB的表达盒进入表达LPS信号转导受体的细胞系中; 混合纯化的MD-2(髓样分化蛋白-2),LPS和治疗败血症的蛋白质治疗剂的步骤; 使混合物与细胞系接触的步骤; 以及当报道蛋白的表达水平低于对照组时,确定接触的实验组是否具有比对照组更高的功效的步骤。 (参考号)(AA)Luciola cruciata萤光素酶; (BB)海肾萤光素酶; (CC)LAR II试剂; (DD)停止&发光试剂; (EE)萤火虫/ Renilla = TLR4 / MD-2激活指数; (FF)TMB底物; (GG)细胞因子TNF-α,IL-6等
    • 3. 发明公开
    • 신규한 MD-2 결합 폴리펩타이드 및 이의 용도
    • 新型MD-2结合多肽及其用途
    • KR1020120022453A
    • 2012-03-12
    • KR1020100086055
    • 2010-09-02
    • 한국과학기술원한국생명공학연구원
    • 김학성이상철한지은이중재김동섭홍승표박근완이승구하재석김유정
    • C07K19/00C12N15/62C12N15/63A61P31/00
    • PURPOSE: A novel polypeptide which specifically binds to MD-2 protein is provided to design a therapeutic agent protein for treating sepsis using VLR scaffolding protein. CONSTITUTION: A polypeptide which specifically binds to MD-2(myeloid differentiation protein-2) protein fused N-terminal of internalin B protein, VLR(vriable lymphocyte receptor)-modified repetitive module, and C-terminal of VLR protein. The polypeptide is sequence number 2, 3, 4, or 5. A repetitive module with high stability through consensus design is a repetitive module of sequence formula 1(LTNLxxLxLxxNQLQSLPxGVFDK). A method for preparing the polypeptide comprises: a step of preparing a vector containing a nucleic acid encoding the polypeptide; a step of introducing the vector to host cells; and a step of collecting polypeptides from the host cells.
    • 目的:提供特异性结合MD-2蛋白的新型多肽,以设计使用VLR脚手架蛋白治疗败血症的治疗剂蛋白质。 构成:特异性结合MD-2(骨髓分化蛋白-2)蛋白的多肽融合内蛋白B蛋白的N末端,VLR(可变淋巴细胞受体)修饰的重复模块和VLR蛋白的C末端。 多肽是序列号2,3,4或5.通过共有设计具有高稳定性的重复模块是序列式1(LTNLxxLxLxxNQLQSLPXGVFDK)的重复模块。 制备该多肽的方法包括:制备含有编码该多肽的核酸的载体的步骤; 将载体引入宿主细胞的步骤; 以及从宿主细胞收集多肽的步骤。